MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ene.16043

Медицинская библиотека · European journal of neurology · 2023

Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study.

Verschoof Merelijne A, van Meenen Laura C C, Andriessen M Valérie E, Brinkman Daniëlle M C, Kamphuis Sylvia, Kuijpers Taco W, Leavis Helen L, Legger G Elizabeth, Mulders-Manders Catharina M, de Pagter Anne P J, Rutgers Abraham, van Well Gijs T J, Coutinho Jonathan M, Hak A Elisabeth, van Montfrans Joris M, Klouwer Femke C C

СтатьяКомментарийПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: Patients with adenosine deaminase 2 (ADA2) deficiency can present with various neurological manifestations due to vasculopathies and autoinflammation. These include ischaemic and hemorrhagic stroke, but less clearly defined neurological symptoms have also been reported.

METHODS

In this cohort study, patients with confirmed ADA2 deficiency from seven university hospitals in the Netherlands were included. The frequency and recurrence rates of neurological manifestations before and after initiation of tumor necrosis factor α (TNF-α) inhibiting therapy were analyzed.

RESULTS

Twenty-nine patients were included with a median age at presentation of 5 years (interquartile range 1-17). Neurological manifestations occurred in 19/29 (66%) patients and were the presenting symptom in 9/29 (31%) patients. Transient ischaemic attack (TIA)/ischaemic stroke occurred in 12/29 (41%) patients and was the presenting symptom in 8/29 (28%) patients. In total, 25 TIAs/ischaemic strokes occurred in 12 patients, one after initiation of TNF-α inhibiting therapy and one whilst switching between TNF-α inhibitors. None was large-vessel occlusion stroke. Two hemorrhagic strokes occurred: one aneurysmatic subarachnoid hemorrhage and one spontaneous intracerebral hemorrhage. Most neurological symptoms, including cranial nerve deficits, vertigo, ataxia and seizures, were caused by TIAs/ischaemic strokes and seldom recurred after initiation of TNF-α inhibiting therapy.

CONCLUSIONS

Neurological manifestations, especially TIA/ischaemic stroke, are common in patients with ADA2 deficiency and frequently are the presenting symptom. Because it is a treatable cause of young stroke, for which antiplatelet and anticoagulant therapy are considered contraindicated, awareness amongst neurologists and pediatricians is important. Screening for ADA2 deficiency in young patients with small-vessel ischaemic stroke without an identified cause should be considered.

Для цитирования: Verschoof Merelijne A, van Meenen Laura C C, Andriessen M Valérie E, Brinkman Daniëlle M C, Kamphuis Sylvia, Kuijpers Taco W, Leavis Helen L, Legger G Elizabeth, Mulders-Manders Catharina M, de Pagter Anne P J, Rutgers Abraham, van Well Gijs T J, Coutinho Jonathan M, Hak A Elisabeth, van Montfrans Joris M, Klouwer Femke C C. Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study.. European journal of neurology. 2023. DOI: 10.1111/ene.16043.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.